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In the hamster to rat liver transplant model, we 
determined the efficacy of tacrolimus in attenuating 
natural xenospecific humoral immunity and in abro-
gating the hyperacute liver rejection that is produced 
by presensitizing the Lewis rat recipient. Hamster liv-
ers, transplanted orthotopically into naive rats (con-
trols), were rejected with animal death after 6.4±0.5 
(SD) days. The infusion on (day -6) of 1.5 x 107 hamster 
hepatocytes, or of 1.5 x 108 nonparenchymal cells 
(NPC), resulted in hyperacute rejection and death in 
s1.9 days. However, when the rats were pretreated 
with 1 mglkg/day tacrolimus from days -6 to -1, sur-
vival of non-presensitized animals was prolonged to 
25±20 days and that of recipients presensitized with 
hamster hepatocytes to 36±16 days or with NPC to 
32±1.7 days. The tacrolimus pretreatment signifi-
cantly reduced the hamster-specific complement-de-
pendent cytotoxic antibodies response directed to 
liver NPC but not to lymph node cell targets. These 
observations suggest that the prolongation of survival 
by appropriately timed treatment with this T cell di-
rected drug model is caused by the inhibition of hu-
moral as well as cellular xenograft rejection. 
The consequences of humoral immunity in xenotransplant 
models are dictated by the species combination (1, 2), the 
kind of organ that is engrafted (3), and the direction of organ 
transfer between the species (4, 5). With the appropriate 
selection of these variables, xenograft survival in an unal-
tered recipient may range from a few minutes (hyperacute 
rejection [HAR*]) to several days. In the longer survival 
models, species-specific xenosensitization of the recipient 
produces HAR (6-10). For example, the humoral rejection in 
3 days of abdominally placed hamster hearts is converted in 
presensitized rats to HAR that is complete in < 10 min (6, 
8-1Ol. In contrast, when the antibody resistant hamster liver 
is transplanted under the same circumstances of presensiti-
zation, the reduction in survival is from 7 to <2.0 days (11). 
Untreated nude (T-cell deficient) rats reject hamster heart 
grafts at the same 3 days as in normal rats (12-14), ostensi-
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bly in accord with a T-cell independent mechanism of hu-
moral xenograft rejection. However, the pre sensitization pro-
cedure that caused HAR within 10 min in normal rats 
resulted in prolonged xenograft survival in all nude rat re-
cipients, and, in 4 of 10 experiments, survival exceeded 100 
days (15). This observation, coupled with the demonstration 
of a remarkably obtunded antibody response in the presen-
sitized nude recipients, prompted the experiments in normal 
Lewis rats reported here in which the nude rat environment 
was mimicked with a 6-day pretransplant course of the T-cell 
directed immunosuppressant tacrolimus. Tacrolimus pre-
treatment alone did not reduce the titer of preformed xeno-
specific antibodies. However, it abrogated HAR of hamster 
hepatic xenografts by presensitized rats, and it prolonged the 
survival of the transplanted livers several times beyond that 
in untreated recipients, whether or not the presensitization 
protocol had been applied. The results suggest that, contrary 
to current consensus, an antibody subclass(es) important for 
humoral xenograft rejection is T-cell dependent, thereby ex-
posing a potential seam in the xenotransplant barrier that 
may be susceptible to classic immunologic manipulation in-
cluding tolerance induction. 
MATERIALS AND METHODS 
Animals and Procedures 
Animals. Outbred male Syrian Golden hamsters (110-120 g) and 
male Lewis rats (LEW, RT1 1, 180-220 g) obtained from Charles 
Rivers Laboratories (Wilmington, MA) were used as donors and 
recipients. respectively. The animals were maintained in the patho-
gen-free facilities of the University of Pittsburgh Medical Center and 
provided with Purina rodent chow and tap water ad libitum. 
Orthotopic liver transplantation. Hamster livers were trans-
planted orthotopically into LEW recipients and revascularized with 
a combination of suture and cufT techniques (3, 16), All operative 
procedures were performed under methoxyflurane (2,2-dich9Ioro. 
1 ,1-difluoroethyl methyl ether, Pitman-Moore, Mundelein. ILl anes· 
thesia. The diagnosis of HAR was made when after reperfusion; the 
liver surface appeared mottled with residual red patches culminat· 
ing in the early death of the recipient. Confirmatory histopatholog-
ical examination was done in all experiments. 
Isolation of Cells 
Hepatocytes. Hepatocytes (HC) from hamster livers were isolated 
using the in situ collagenase (Type A, 0.5 mg/ml, Boehringer Mann· 
heim, IN) perfusion technique (J 7l. Briefly, livers were initiallY 
perfused with a calcium-free solution containing EGTA (Sigma 
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Chemical Co., St. Louis, MOl followed by collagenase for 30 min. The 
HC were then purified by differential centrifugation (50xg) for 2 min 
using a 30% Percoll (Sigma) gradient. Hepatocyte purity as assessed 
by microscopic analysis was consistently more than 98% and the 
viability as determined by trypan blue dye exclusion exceeded 95'7c. 
Nonparenchymal cells. Nonparenchymal cells (NPC) from ham-
ster liver were isolated with the ex vivo protease and deoxyribonu-
clease method (18). After in situ perfusion with Gey's balanced salt 
solution (Life Technologies Inc., Grand Island, NY), the liver was 
excised and minced. The fragments were treated by constant stirring 
for 10 min at 37°C in 100 ml of a solution containing protease (2 
mg/ml) and DNAase <0.5 mg/mll, to which fresh DNAase solution 
was added every 20 min. NPC were purified from dead cells and 
hepatocytes by centrifugal elutriation <Beckman Elutriator Model 
#J-6M, Beckman Instruments Inc., Palo Alto, CAl. This procedure 
yielded NPC with a purity and viability of >95%. The leukocyte 
composition was principally mononuclear cells of myeloid lineage 
with a minority population of lymphocytes. The NPCs also included 
endothelial cells. 
Experimental Design 
The experimental design is summarized in Table 1. In experi-
ments involving tacrolimus (a gift from Fujisawa Pharmaceutical 
Co., Osaka, Japan), the drug was administered at 1 mg/kglday from 
days -6 to -1 followed by orthotopic liver transplantation on day 0 
(Table 1). No postoperative treatment was given. 
Intravenous donor species cell infusion was with 1.5x 107 NPC or 
HC on day -6 except in group 4 (Table 1) where a 10-fold dose of 
NPC was administered (1.5xl08 ). 
Antibody Studies 
Complement·dependent cytotoxicity. These studies were per-
formed only in the animals of group 1 (control) and groups 2, 5, and 
6. The titers of serum anti-hamster antibodies (Ab) on the day ofliver 
transplantation (day 0) were determined with a 2-step CDC assay in 
which hamster lymph node (LN) and liver NPC (which included 
endothelial cells) were the targets. Duplicate samples of 5 X 103 cells 
in 1 ILl of RPMI were placed into each well of a 72-well tissue-typing 
tray (Robbin Scientific, Sunnyvale, CAl. Decomplemented recipient 
serum (1 ~ per well) was then added, and the plates were incubated 
for 30 min at room temperature. At the end of this incubation, 2 ILl 
of baby rabbit complement (1:10, Cedarlane Labs, Hornby, Ontario, 
Canada) were added to each well and incubated for an additional 30 
min at 37°C in 5% CO2 in air. Cell viability was determined by 
adding 5 ILl of 0.4% trypan blue solution to each well. The Ab titer 
was defined as the highest dilution of serum in which there was lysis 
of 30% of the cells. 
Characterization of serum immunoglobulins. Using a sandwich 
ELISA, the concentrations of total rat IgG and IgM were determined 
on day 0 in the sera of animals in each experimental group. Goat 
anti-rat IgM or IgG Ab (Accurate Chemical and Scientific Co., West-
bury, NY), 100 ILl (10 lLg/ml in Na2C03 buffer, pH 9.6), were added to 
each well of a 96-well microtiter plate, incubated overnight at 4°C 
and washed 3 times with PBS containing 0.05% Tween-20 (Sigma). 
Nonspecific binding was blocked by adding 200 ml of 5% goat serum 
(in PBS) for 30 min. After washing, 100 ILl of the sample being 
assessed was placed in each well and incubated for 2 hr at room 
temperature. Each well was washed 4 times and incubated for an 
additional 3 hr at room temperature with 100 ILl of affinity-isolated 
peroxidase-conjugated goat anti-rat IgM or IgG Ab (1:104 dilution, 
Accurate). 
The reaction was developed using 200 ILl/well of O-phenylenedi-
amine dihydrochloride (0.4 mg/ml SIGMAFAST OPD Tablet, Sigma) 
solution as a substrate followed, by measurement of optical density 
at 490 nm using a kinetic microplate reader (Molecular Devices, 
Menlo Park, CAl. The results obtained were compared with those of 
known rat IgM or IgG standards that were run simultaneously with 
the test samples. 
Assay for hamster NPC-specijic antibodies. NPC (2x 106 ) isolated 
from hamster liver were incubated for 60 min with 500 1-'1 of serum 
obtained from animals in each group. At the end of this incubation, 
the cells were lysed by suspending them in 3M KCI solution for 3 
min. The presence of hamster NPC-specific IgM and IgG Ab was 
determined by sandwich ELISA assay (see Characterization of serum 
immunoglobulin section). 
Immunocytochemistry. A direct immunofluorescence technique 
was used to visualize the deposition of rat immunoglobulins OgM or 
IgG) in hamster liver xenograft samples obtained 10,30,60,180, and 
360 min after their revascularization. Cryosections were incubated 
for 60 min with FITC-conjugated goat anti-rat IgM or IgG Ab. After 
washing, the slides were viewed on a Nikon epifluorescent micro-
scope (Nikon Instrument Group, Melville, NJ) equipped with a DAP! 
(FITC) Texas-Red triple band pass filter (Fryer Co., Huntley, IL). 
Anti-hamster Ab in rat recipients also was determined by incu-
bating their sera (1:20) with cryosections obtained from normal ham-
ster livers. Their binding was then visualized using FITC-conjugated 
goat anti-rat IgG or IgM Ab. The degree of deposition was evaluated 
as fluorescence intensity from weak ( - ) to strong ( + + + ). 
TABLE 1. Hamster to rat liver xenograft survival 
Group Treatment 
Without Immunosuppression: 
1 Untreated 
2 
3 
4 
HC" 
NPC" 
With Immunosuppressionc : 
5 Tacrolimus 
6 
7 
HC l + Tacrolimus 
NPC1 + 
Tacrolimus 
n 
10 
10 
10 
4 
11 
11 
10 
.. 1.5x 107 of hepatocytes (HC) or nonparenchymal cells (NPC) were infused iv on day -6. 
b 1.5XI08 NPC infused iv on day -6. 
c 1 mg/kg/day of tacrolimus im from -6 to -1. 
Survival (days) p (X::SDl 
6.4:!:0.5 
"'-:s-- <0.05 1.9:!:1.4 ... 
5.3±0.7 
<0.05 
1. 7 :!:1.2 
25:!:20 ... -
<0.002 
36:!:16 ... ~ 
32::1.7 
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RESULTS 
Xenograft Survival 
Without immunosuppression. Hamster livers, when trans-
planted into naive rat recipients, were rejected in 6.4:!:0.5 
(8m days (group 1, Table 1). Recipients pretreated on day -6 
with 1.5x107 HC third party hamster HC had HAR of the 
subsequently transplanted hamster livers with death after 
1.9::!:1.4 days (group 2, Table 1, Fig. 1A). The HAR was 
obvious immediately after revascularization. Although the 
same dose of NPC did not cause HAR (group 3), a 10-fold 
increase of NPC also caused HAR in 1.7:!: 1.2 days (group 4, 
Table 1). 
With immunosuppression. The preoperative course of ta-
crolimus resulted in significantly prolonged survival 
(25:!:20d) of the otherwise unaltered xenograft recipients 
(group 5, Table 1). Of greater interest, tacrolimus prevented 
HAR in animals presensitized with HC (Fig. 1B). The 36:!: 16 
day survival of the HC-augmented animals exceeded by 11 
days that of recipients pretreated with tacrolimus only 
(P=O.1 N8). 
FIGURE 1. Rat IgM on cryosections of hamster liver xenograft 10 min 
after reperfusion in rat recipients. (A) Marked deposition of IgM on 
cells lining the sinusoids of recipients pre sensitization with hamster 
HC. (8) Minimal IgM deposition after HC pretreatment but with a 
6-day preoperative course of tacrolimus. No staining was observed 
when sections of livers obtained from normal hamsters were stained 
with FITC·conjugated goat anti-rat IgM antibodies tnegative con-
trols) (x200l. 
Antibody Studies 
Cytotoxic antibodies. Anti-hamster Ab titers (2-step com-
plement-dependent cytotoxicity assay) are shown in Figure 2. 
The liver NPC targets were less susceptible to lysis than the 
LN cell targets when tested against preoperative sera ob-
tained from either untreated (Fig. 2A) or tacrolimus-treated 
recipients (Fig. 2D). The NPC susceptibility was increased 
almost to that of the LN cells in animals presensitized with 
HC (Fig. 2B), but this was reduced to control levels in rats 
also pretreated with tacrolimus (Fig. 2C). The anti-NPC and 
anti-LN cell cytotoxic activity shown in all 4 panels was 
mediated by IgM Ab, because it was largely eliminated by 
dithiothreitol (DDT; Eastman Fine Co., Rochester, NY) (data 
not shown). 
Total and NPC-specific IgM and IgO. Pretreatment with 
neither tacrolimus nor HC affected the concentration of total 
IgM or IgG concentration in the rat preoperative sera in the 
different groups (Fig. 3). 
The specificity of IgM binding in the hamster livers 10 min 
after reperfusion is shown in Figure 4. This was significantly 
increased in the rats infused with HC. Paradoxically, binding 
was increased slightly when the recipient animals had been 
pretreated with tacrolimus alone or in conjunction with HC 
(Fig. 4A). NPC-specific IgG Ab followed the same pattern, but 
the changes compared with control were not significant (Fig. 
4B). 
Immunocytochemistry. Livers transplanted into un-
treated animals had moderate deposition ofIgM Ab (Table 2) 
and IgG Ab (data not shown) in serially biopsied samples, 
10-360 min postreperfusion. The single color immunofluo-
rescence staining was primarily observed along the sinusoids 
with much more IgM than IgG. Tacrolimus pretreatment did 
not reduce the intensity of staining (Table 2), suggesting that 
the drug had no effect on the production of natural Ab. 
In contrast, the findings were dramatically changed by 
pretreatment with HC in the absence of tacrolimus. These 
xenograils had markedly increased deposition of IgM (but 
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FIGURE 2. CDC assay of rat recipient serum on day 0 (pre-liver 
transplant) using hamster LN cells (.) or liver NPC (e) as targets. 
(A) Naive rat sera. (B> Sera obtained from recipients presensitized 
with donor species He. (C) Sera from rats presensitized with HC but 
given 6 day pre-operative course oftacrolimus. (0) Six day pretreat-
ment with tacrolimus only. Note that selectively increased cytotox-
icity to NPC caused by HC infusion (B) was prevented by course of 
tacrolimus tCL 
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FIGURE 3. Total rat IgM (closed bars) and IgG antibodies (open bars) 
on day 0 (pre-liver transplant) in the sera of naive rats (NRS) and in 
animals pretreated with HC (group 2). The quantity of these anti-
bodies remained unaltered in the sera of all these animals. Hepato-
cytes plus tacrolimus (HC + FK, group 6), or tacrolimus (FK) only 
(group 5). 
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FIGURE 4. The concentration of NPC-specific rat anti-hamster (A) 
IgM and (El IgG antibodies, determined in the same experimental 
groups shown in Figure 3. The bar graph depicts the quantity of 
NPC-specific immunoglobulins, and the line indicates their percent-
age of the same sera. Note the differing effect on NPC·specific IgM by 
different pretreatment regimens without comparable modulation of 
NPC·specific IgG. 
TABLE 2. Rat anti·hamster IgM antibody deposition by direct 
immunofluorescence staining and hamster to rat xenotransplanted 
livers to rat xenotransplanted Liversu 
Time Post· Untreated Tacrolimus HC HC + 
perfusion I mml (gTOUp 1) Igroup 51 I group 21 Tacrolimus (group 61 
10 :: :: ++-t- :: 
30 + + +++ :!: 
60 + + ++ + 
180 + + ++ :: 
360 + + ++ :!: 
" Scored as weak ( -) to strong ( + + + I deposition. The treatment 
regimens were as in Table 1. 
not IgG) at all times sampled (group 2 in Table 2 and Fig. l). 
Remarkably, postperfusion IgM deposition in the livers of 
animals pretreated with the combination of HC and tacroli-
mus was less than in either untreated controls or in animals 
treated with tacrolimus only (group 6 in Table 2 and Fig. 1). 
The titer and isotype of rat anti-hamster Ab obtained 
preoperatively from the recipients in different groups was 
also determined by staining cryosections of normal rat livers 
with these recipient sera (data not shown). All serum sam-
ples tested contained more IgM than IgG Ab. However, the 
titer of these pretransplant Ab was greatest in recipients 
pretreated with HC only; intermediate and similar in naive 
animals and those pretreated only with tacrolimus; and least 
when both HC and tacrolimus were used for treatment. 
DISCUSSION 
Although a different organ was used for the present liver 
transplant experiments, the observations support the conclu-
sion from our earlier nude rat studies with heart transplan-
tation (15) that humoral rejection is T-cell modulated in the 
hamster to rat models. This was easier to demonstrate with 
the liver model because the unusual resistance of hepatic 
allografts (19, 20) and xenografts (21) to antibody injury 
expands the observational time frame. 
The 6-day pretransplant course of tacrolimus in normal 
rats had no demonstrable effect on the preexisting rat anti-
hamster IgM Ab. However, this course of T-cell directed 
treatment prevented the rise in xenospecific antibody titer 
otherwise caused by the sensitization protocol or by trans· 
plantation. Avoidance of the antibody storm correlated with 
avoidance of hyperacute rejection, and with a paucity of Ig 
deposition in the graft. The duration of survival in the ab-
sence of any posttransplant therapy far exceeded that in 
naive recipients and was at least as good (especially in ani-
mals with the pre sensitization protocol) as can be achieved 
by giving continuous postoperative tacrolimus in the same 
daily dose range (22). 
It is a general rule in adaptive immunity that the activa-
tion by protein antigen of most naive B cells is thymus-
dependent and requires accessory signals that come from an 
armed helper T cell (23). However, many bacteriallipopoly-
saccharides, polysaccharides, and polymeric proteins are 
classified as thymus·independent (Tn antigens because in 
the absence of T cells they can directly induce B cells to 
produce antigen specific antibody, or in higher concentration 
induce polyclonal activation (24-28). According to the con-
sensus literature, there are 2 classes of TI antigens: TIl' 
which can directly activate immature and mature B cells; 
and TI2 (limited to polysaccharides), which can activate ma-
ture B cells only. 
However, there is a possibility that the thymus indepen-
dence of these TI B cells is not absolute. Although nude mice 
respond to qf~ antigens, depletion of all T cells in culture 
eliminates these responses, which can be restored by adding 
back very small numbers ofT cells (30), Responses to several 
TI2 polysaccharide antigens have been shown to be domi-
nated by a subpopulation of B cells that have CD5 and 
IgM+ +briRhtlIgDd,m surface expression. These cells arise from 
an immature stem cell early in ontogeny, secrete IgM > > > 
IgG, and may, under some conditions, respond to protein as 
well as polysaccharide antigen (29). Their responses do not 
induce significant Ig class switching or somatic hypermuta-
tion of immunoglobulin variable (V) regions. As a conse-
quence. their predominant antibody isotype is IgM, which is 
augmented by IL-5 and to an unknown extent by T cells. 
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Much of the immunoglobulin found in normal serum is pro-
duced by these cells whose function is not yet fully known 
(31). 
It has been suspected for several years that the CD5 cells 
may be important for, or critical to, the xenogenic response. 
We have reported a striking and specific activation of 
IgM++bright/lgDdim cells in the spleen after hamster to rat 
heart and liver transplantation (32). Congruent with these 
findings, Wu et al. (33) and Borie et al. (34) have identified 6 
monoclonal IgM secretory products after hamster to rat heart 
transplantation, of which 4 with essentially identical se-
quence caused hyperacute rejection with passive transfer. 
These antibodies were strongly reactive with the sialyl-Lewa 
epitope of a glycoprotein and less so with several other oli-
gosaccharides. These observations and the similarity of the 
hamster epitope to the a-galactosyl carbohydrate target of 
pig to human xenotransplantation (35-37) suggest that there 
is a family of polysaccharide epitopes (with variations) that 
constitutes the prohibitive barrier to interspecies transplan-
tation. 
It was shown in the investigations of Wu et al. (33) and 
Borie et a1. (34) that the V gene segments that encode CD5 
B-cell receptors in the rat are evolutionarily selected to rec-
ognize common bacterial antigens and contribute to early 
phases of (innate) immunity. It goes without saying that the 
drastic modification of this "innate" response with the T cell 
deficient state (15) or by a T-cell directed immunosuppres-
sant in the present study is surprising and potentially rele-
vant clinically. It is noteworthy that Sablinski et al. (10) 
observed the same effect of abrogated HAR in the sensitized 
hamster to rat heart model using an anti-CD4 mAb. The 
ability of an immunosuppressant to prevent donor species 
presensitization and coincidentally induce short-term species 
specific tolerance was first described with deoxyspergualin 
(9) and ascribed at the time to a direct B cell inhibition. 
However, it is now recognized that the manifold actions of 
DSG include potent T-cell suppression (38, 39). 
The evidence that the xenospecific humoral response can 
be T-cell modulated may be the soft spot in the xenograft 
barrier for which experimentalists have been probing. It is 
important, therefore, to determine if these findings are rele-
vant to other species combinations including those in which 
humans are recipients. Most preclinical immunosuppressive 
regimens or other strategies developed for xenotransplanta-
tion have been based on the assumption that control ofT- and 
B-cell activation requires drugs or interventions (such as 
splenectomy) that are specific to each lymphocyte population 
(22). The use of B-cell selective drugs will undoubtedly con-
tinue to playa role in xenotransplant cocktails designed for 
potential clinical use. However, treatment protocols exploit-
ing pretransplant and continued postoperative T-cell modu-
lation of humoral immunity may have an unexpectedly im-
portant role. 
Although established only in the hamster to rat combina-
tion, this strategy may be applicable to other species combi-
nations and to specific allotransplant syndromes ofHAR (Le., 
ABO incompatibility and presensitization), which we believe 
to have the same pathogenesis in principle as the HAR of 
xenografts (5). Of interest, T-cell deletion with thoracic duct 
drainage (TDDl, in patients with preformed antibody states 
was attempted 15-20 years ago with moderate success in 
avoidance of HAR (40, 41 I, based on the demonstration by 
MacGregor and Gowans (42) that TDD in rats sharply re-
duced humoral as well as cellular immune responsiveness 
within 5 days. In a classic human study of nontransplant 
patients, Machleder and Paulus (43) established that the 
required duration of TDD to virtually eliminate ABO isoag-
glutinins (which resemble anti-a-galactosyl antibodies [37]) 
was 30 days. Although TDD is an obsolete method of lym-
phoid depletion, the lessons from these trials should not be 
forgotten. 
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